Xarelto lawsuits are currently being filed on behalf of individuals that experienced uncontrollable bleeding events. Xarelto and other drugs like Pradaxa and Eliquis are blood thinners designed to prevent strokes and blood clots.
Xarelto, Pradaxa, and Eliquis Linked to Uncontrollable Bleeding
In recent years, new oral anticoagulants such as Xarelto, Eliquis and Pradaxa have taken over a lot of the market formerly owned by warfarin, because of their “convenience.” Marketed as requiring less effort in blood tests and managing food interactions, these new anticoagulants also carry a risk that was not present in warfarin – no antidote to stop uncontrolled bleeding. Many times the ability to reverse the effects of Xarelto, Eliquis or Pradaxa can be a matter of life or death.
According to the Institute of Safe Medicines Practices (ISMP), a watchdog group, anticoagulant drugs are a “high-risk treatment” and cause bleeding in approximately 15% of patients with atrial fibrillation. Many physicians are wary of the new anticoagulants, since there is limited evidence on how to manage bleeding in patients taking them since there is no known reversal of the anticoagulant effect.
Instant Case DecisionSee if you qualify for Xarelto Lawsuits or Pradaxa Lawsuits and the right to potentially significant financial recovery.
The Xarelto / Pradaxa Instant Case Evaluator provides Pradaxa and Xarelto lawsuits information, qualification and details regarding your situation.
- Did you or a loved one take Xarelto or Pradaxa?
- Did a bleeding event then develop in you or your loved one?
New anticoagulants such as Xarelto, Eliquis and Pradaxa have been linked to an increased number of uncontrollable blood injuries because there was no approved antidote for patients who use the medication.
Pradaxa Lawsuit Settlement
In May 2014, nearly 4,000 individuals harmed by uncontrollable bleeding with the drug Pradaxa received $650 million in compensation for their injuries. More Pradaxa Lawsuits are moving forward today for individuals who were harmed prior to the FDA approval of a Praxbind in October 2015, when the FDA
Xarelto Lawsuits Move Forward
Xarelto is at the center of numerous lawsuits claiming personal injury and wrongful death. Plaintiffs allegedly suffered uncontrollable bleeding which resulted in severe injuries and deaths caused by Xarelto. Xarelto lawsuits accuse the manufactures of failing to adequately warn consumers and doctors of the side effects that can occur with an uncontrollable bleed and hiding important safety information which resulted in over a hundred deaths and over thousands of fatal injuries.
Almost 20,000 Xarelto lawsuits have been centralized in federal multidistrict litigation (MDL) in U.S. District Court, Eastern District of Louisiana, where Judge Eldon Fallon selected four bellwether cases that resulted in defense verdicts. A fourth bellwether trial is set to begin on December 2.
On the other hand, a jury in Philadelphia, swiftly found Bayer to be at fault for the gastrointestinal bleeding of Lynn Hartman, the first trial to go forward in Pennsylvania state court. In December 2017, the jury awarded Xarelto plaintiff Lynn Hartman $28 million – with $26 million of them assigned as punitive damages designed to send a message to Bayer. This case was later thrown out by a state judge after hearing arguments that the plaintiff’s doctor testified that additional warnings would not have changed her decision to prescribe the drug. There are than 1,500 cases remaining in state court in Pennsylvania and more cases filed in state court cases in Pennsylvania, Delaware, and California.
The first Xarelto bleeding lawsuits were filed against Bayer Healthcare Pharmaceuticals, Inc. and Johnson & Johnson (and its subsidiary Janssen Pharmaceuticals, Inc.) in early 2014. This and other Xarelto lawsuits claim that the drug makers were negligent in promoting Xarelto as a safe and effective alternative to warfarin that do not require the same kind of stringent monitoring required of warfarin.
But many experts believe that monitoring is actually more important for Xarelto should catastrophic bleeding events occur, since the drug has no approved reversal agent. In October 2015, the FDA approved Praxbind, a reversal agent specifically created for Pradaxa.
Xarelto Lawsuits are currently moving forward in the Eastern District of Louisinana presided by the Honorable Kurt D. Engelhardt with the first Bellwether trials set to move forward in February 2017.
Xarelto / Pradaxa Injuries & Side Effects
Most Serious Complications
|Gastrointestinal bleeding||Rectal bleeding|
|Hernia Recurrence||Adhesion (Scar-like tissue that sticks tissues together)|
|Heart Attack||Pulmonary Embolism|
|Epidural Hematoma||Brain Hemorrhage|
Anticoagulant Drugs With No Reversal Agent Still On The Market
The risk of bleeding is a problem with all blood thinners, however, with warfarin, doctors can turn to an “antidote” of Vitamin K to stop the bleeding. Xarelto and Eliquis do not currently have an antidote to stop a severe, life-threatning bleed. However, five years after approval, in October 2015, an antidote for Pradaxa, Praxbind, was finally FDA approved.
Xarelto / Pradaxa Frequently Asked Questions
Sometimes you need a lawyer near you and sometimes its best to hire a lawyer based on the lawyer’s resources and experiences.
The right lawyer for mass-tort litigations may not be your local lawyer. The 18,000 Xarelto Product Liability litigation cases have been consolidated into a single courtroom in New Orleans and the work of moving these cases forward in the most effective and efficient way are being done by lawyers with experience in the multidistrict litigation process.
When considering a Xarelto lawyer, you should consider a law firm that has the ability to represent clients in all 50 states, and one that has the resources to take on a large corporation like Bayer – TruLaw is not afraid to take on the largest drug and medical device companies in the world. We work with trusted legal affiliates to make sure that TruLaw clients have the resources and experiences needed to hold big business accountable when they put profits over people.
Your Xarelto or Pradaxa lawsuit is designed to help you financially recover from injuries that were caused by someone else. We hope putting your trust in TruLaw will take away your concern of protecting your legal rights., but it is most important to us that you spend your time recovering physically.
Your Xarleto or Pradaxa lawsuit should assist in covering your medical bills, the amount of income and benefits that you lost as a result of your injury and, if your injuries are permanent, we will look to recover for your permanent disfigurement.
In addition, it is always our hope that your Xarelto or Pradaxa lawsuit will help us to remove dangerous drugs, toxins and devices from the market. We are not only lawyers, but also safety advocates that believe in getting information out to the public so no more people are injured. We hope you will join us in the role as a safety advocate.
We often hear injured people refer to their personal injury case as a “class action” because their case was grouped together in a lawsuit with other injured people. This is most often NOT the case. Xarelto bleeding injuries are not being litigated as class action cases. Often, individual cases are grouped together so the attorneys and judge can address common procedural issues initially, saving time for the injured parties and the court, but this is very generally referred to as a “mass tort.”
A Mass tort refers to civil actions involving numerous plaintiffs against one or a few corporate defendants in state or federal court. Class actions are mass torts that are generally used on financial losses and multidistrict litigations (MDL) are generally used on personal injury claims, often in product liability cases.
Xarelto cases have been consolidated into an MDL in a federal court in the Eastern District of Louisiana. There are more than 18,000 plaintiffs that have incurred injuries from Xarelto consolidated into MDL 2592 – Xarelto Products Liability Litigation under the Honorable Eldon E. Fallon. As of now, there have been no plaintiff victories in Xarelto MDL in the federal courts.
In addition to the MDL, many plaintiffs are searching for justice in state courts where there have been similar consolidations used to move cases through swiftly. There has been one case tried in Philadelphia, where a verdict of $28 million was awarded to the plaintiff. There are more than 1,500 cases remaining in Philadelphia and more cases in State courts in California and Delaware.
Cases have been moving forward in both Pennsylvania and New Orleans but as of today, there have been no public settlement offers by Bayer for those injured by uncontrollable bleeding as a result of taking Xarelto.
We understand the frustration in waiting to hear about settlements and will keep the public posted as we learn of them.
Xarelto lawsuits are currently being filed and consolidated for trials in a federal mulit-district litigation in the Eastern District of Louisiana in New Orleans. In addition, some Xarelto lawsuits have been moving through state courts in Pennsylvania, Delaware and California.
Each of the Xarelto lawsuits claim they were harmed by uncontrollable bleeding and were not warned of the risk that Xarelto carried. In addition, plaintiffs are holding Bayer responsible for the injuries that resulted as a result of the lack of antidote for Xarelto.
TruLaw is pursuing Xarelto and Pradaxa Lawsuits because we believe consumers were not properly warned of the risks of injury.
Have you or a loved one suffered from internal bleeding?
Did this recent Xarelto or Pradaxa commercial grab your attention? Did you find our site because you were wondering if you or your loved one qualifies for compensation as this commercial suggests?
We built the Xarelto Instant Case Evaluator as a no cost/no obligation place for you to find out if this commercial applies to you. We understand that you have concerns and you need answers – and we are here to help. We provide you this valuable information so you are prepared to talk to a lawyer – free of charge and with no obligation.